A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY
Latest Information Update: 05 Dec 2023
At a glance
- Drugs Danuglipron (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Dec 2023 According to Pfizer media release, pharmacokinetic data from this trial anticipated in the first half of 2024.
- 01 Dec 2023 Primary endpoint (Percent change from baseline in body weight) has been met as per results published in the Pfizer Media Release
- 01 Dec 2023 Results published in the Pfizer Media Release